Sotorasib for Stage IV Lung Cancer

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Stage IV Lung Cancer+5 MoreSotorasib - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial studies the effect of AMG 510 in treating patients with KRAS G12C mutated non-squamous non-small cell lung cancer.

Eligible Conditions
  • Stage IVB Lung Cancer
  • Non-Squamous Non-Small Cell Lung Carcinoma
  • Stage IV Lung Cancer
  • Lung Adenocarcinoma
  • Stage IVA Lung Cancer
  • Non-Small Cell Lung Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: Up to 3 years

Up to 3 years
Duration of response
Incidence of adverse events
Overall survival
Progression free survival
Response rate (confirmed, complete or partial)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

Treatment (AMG 510)
1 of 1

Experimental Treatment

116 Total Participants · 1 Treatment Group

Primary Treatment: Sotorasib · No Placebo Group · Phase 2

Treatment (AMG 510)
Drug
Experimental Group · 1 Intervention: Sotorasib · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sotorasib
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 3 years

Who is running the clinical trial?

Southwest Oncology GroupLead Sponsor
387 Previous Clinical Trials
262,837 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,099 Previous Clinical Trials
41,145,671 Total Patients Enrolled
Sukhmani K PaddaPrincipal InvestigatorSouthwest Oncology Group

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Participants must be assigned to S1900E if their genomic profile shows they have a KRAS^G12C mutation.
People who want to participate in the study must have a brain CT or MRI scan to check for any signs of central nervous system disease within the last 42 days.
If you have HIV and are taking anti-retroviral drugs, your viral load must be undetectable for the last 6 months in order to participate in this study.
and chemotherapy for metastatic non-small cell lung cancer Subjects with EGFR sensitizing mutations, EGFR T790M mutation, ALK gene fusion, ROS1 gene rearrangement, or BRAF V600E mutation must have progressed after treatment with at least one standard of care targeted therapy and chemotherapy regimen for metastatic non-small cell lung cancer.
People who want to participate in this study must have received at least one line of systemic treatment for stage IV or recurrent NSCLC.
People who are participating in this study must have recovered from any side effects they experienced from their previous treatment
You have confirmed stage IV or recurrent NSCLC